REBECCA ABUOR: Open Payments
NPI 1356593974 · ARLINGTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$426 in 15 payments from 6 companies in 2025. Trend: 2023 $300 · 2024 $199 · 2025 $426
Food & beverage: $426
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 6 | $192 |
| Neuronetics, Inc. | 1 | $72 |
| Otsuka America Pharmaceutical, Inc. | 3 | $51 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $41 |
| Supernus Pharmaceuticals, Inc. | 2 | $40 |
| Teva Pharmaceuticals USA, Inc. | 1 | $30 |
Products named: INVEGA SUSTENNA, NEUROSTAR TMS THERAPY SYSTEM, CAPLYTA, Qelbree, UZEDY, SPRAVATO, ABILIFY MAINTENA, ABILIFY ASIMTUFII.
Industry payments across TX — which companies pay providers there.
